Jean-francois Rivassou
Partner at Kurma Partners
Paris, Île-de-France
Overview
Work Experience
Partner
2021 - Current
Founded in Paris in 2009, Kurma Partners has become a key player in financing innovation to build the healthcare industry of tomorrow. Kurma invests in companies from their inception and to finance their growth, across the spectrum of the healthcare sector through its various franchises. These have grown with successive funds in early-stage biotechnology (Biofunds I, II and III), digital health and early-stage diagnostics (Kurma Diagnostics and Kurma Diagnostics 2) and, more recently, growth capital (Kurma Growth Opportunities Fund). Kurma's teams, with a total of 25 people and 10 partners, are based in two offices, in Paris and Munich. They are deeply involved in the European ecosystem and have built up a solid network of international connections with prestigious research institutes, hospitals, entrepreneurs, industry and fellow investors. Kurma Partners is part of the Eurazeo group.
Board Member
2024
PanTera, an IBA and SCK CEN joint-venture, aims to secure the large-scale production of actinium-225 (225Ac), one of the most promising alpha-emitting radioisotopes to fight cancers. By working towards this large-scale production, PanTera’s ultimate goal is to improve the accessibility of future innovative cancer therapy based on 225Ac and theranostics in general. https://pantera-life.com
Board Member
2022
GERMITEC is committed to providing healthcare professionals and patients with safe, simple and automated UV-C solutions for ultrasound probe disinfection, replacing chemistry with photons to radically simplify the lives of healthcare professionals in terms of safety, time and liability. With 15 years of experience in the design and development of sustainable hospital hygiene solutions, GERMITEC is a market leader with a proven track record of product development and sales growth and strong prospects for expansion. www.germitec.com
Board Observer
2018 - 2020
M33, la structure de tête du groupe Theodo, rassemble aujourd’hui 8 entreprises spécialisées dans la création de solutions digitales au service des entreprises : Theodo, Theodo UK et Nimble Ways (Maroc) sont spécialisées dans le web, BAM dans le mobile, Sicara dans la data science et Sipios dans la fintech, Padok dans le Cloud/DevOps, Hokla dans les dispositifs médicaux numériques. www.m33.tech www.theodo.fr www.theodo.co.uk www.nimbleways.com www.bam.tech www.sicara.com www.sipios.com www.padok.fr www.hokla.com
Board member
2015 - 2020
The global high impact advertising market place. Innovative and highly impactful formats available on multi-device. Paris, London, Singapore, Madrid, Milan, Düsseldorf. #Brandtech http://www.sublime.xyz/
Investment Director
2013 - 2020
Investment Director for the ISAI Expansion fund (150m€ Private Equity Fund) at ISAI Gestion (500m€ AUM). Growth equity, secondary deals or LBO/OBO in digital companies. Portfolio companies followed : - Sublime : www.sublime.xyz - Eulerian : www.eulerian.com - M33/Theodo : www.m33.tech - Pandat Finance : www.pandat.fr
Corporate Business Development Manager (M&A)
2006 - 2012
Member of the Management Committee 7 acquisitions completed for a total amount exceeding 30 M€ in France, Germany and UK Figaro Classifieds (Le Figaro Group, formerly Adenclassifieds, listed on Euronext Paris), a French leading online company. Online job and property classifieds and B2B solutions Main websites/brands : cadremploi.fr, keljob.com, explorimmo.com - Sourcing, analysis and selection of acquisition opportunities - Presentation to the Board of Directors, negotiation of contract terms - Supervision of the integration of newly acquired companies - Strategic partnerships with media groups (Web and print) : traffic acquisition, reseller agreements, …
Investment Manager Life Sciences (Biotech/Medtech)
2000 - 2005
VC branch of BNP Paribas More than 300 M€ under management dedicated to early stage investments (IT, Internet and Biotech/Medtech) : - Sourcing, investment in start ups - Follow up (reporting, board meeting, shareholder meeting) - Exits : IPO, trade sale
Assistant to the general manager
1999 - 2000
Nasdaq listed company Genomics and synthetic DNA manufacturing - Sales, logistics, invoicing - Development of the newly established Asian subsidiary - Market and technological intelligence